Group 1 - The core viewpoint of the news is that China Pacific Insurance has successfully invested in Shenzhen Jingfeng Medical Technology Co., Ltd., which has recently gone public on the Hong Kong Stock Exchange, raising HKD 1.199 billion through its IPO at an issue price of HKD 43.24 per share [1] - Jingfeng Medical has achieved significant technological breakthroughs in surgical robots, holding 734 global patents and becoming the first in China and the second globally to receive regulatory approval for three types of surgical robots: multi-port, single-port, and natural orifice [1] - China Pacific Insurance emphasizes its commitment to "value investment and empowering growth," providing stable early-stage funding to support Jingfeng Medical's transition from technology development to commercialization [1] Group 2 - Industry insiders note that the long-term stability of insurance funds aligns well with the long-term capital needs of the GPU industry, highlighting the strategic investment by China Pacific Insurance [2] - In recent years, China Pacific Insurance has focused on key sectors such as integrated circuits, utilizing a diversified product system of "equity + debt" to inject insurance capital into strategic emerging industries, supporting the development of new productive forces [2] - The company plans to continue deepening its technology finance layout and nurturing more "hard technology" enterprises through patient capital, in line with the financial sector's strategic goals [2]
耐心资本助力“ 硬科技” 多家人保寿险投资企业上市